Tongguo Shi | Cancer | Best Researcher Award

Posted on by sciencefather

Dr. Tongguo Shi | Cancer | Best Researcher Award

Tongguo Shi is an Associate Researcher at the First Affiliated Hospital of Soochow University, specializing in cancer immunology and molecular medicine. He earned his PhD from Nanjing University in 2016 and has since focused on tumor immune evasion, immune checkpoint regulation, and colorectal cancer research. His work has been published in leading journals such as Cancer Immunology, Immunotherapy and Cell Death & Disease, with multiple studies highlighting novel therapeutic targets. With expertise in molecular biology and immunological assays, he is dedicated to advancing cancer immunotherapy and precision medicine.

Dr. Tongguo Shi | The First Affiliated Hospital of Soochow University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Tongguo Shi earned his PhD from Nanjing University in 2016, following his undergraduate studies at Liyi University, where he obtained a BA in 2010. His academic journey has equipped him with a strong foundation in medical and biological research, particularly in immunology and oncology.

👨‍🏫Experience

  • Currently serving as an Associate Researcher at the First Affiliated Hospital of Soochow University, Tongguo Shi has been contributing to medical research since December 2021. Prior to this role, he worked as a Research Associate at the same institution from 2017 to 2021, where he gained extensive experience in cancer immunology and molecular medicine. He also served as a Research Associate at the Center of Systems Medicine, Chinese Academy of Medical Sciences, from 2016 to 2017, further strengthening his expertise in cellular and molecular research.

🏆Awards and Recognitions

  • Throughout his career, Tongguo Shi has established himself as a leading researcher, contributing significantly to cancer immunotherapy and colorectal cancer studies. His role as a corresponding author in multiple high-impact journal publications highlights his expertise and recognition in the scientific community. His work on immunological mechanisms in cancer and inflammatory diseases has been widely cited, demonstrating the impact of his research.

💡Skills and Certifications

  • Tongguo Shi specializes in immuno-oncology, with a focus on tumor microenvironments, immune evasion mechanisms, and cancer immunotherapy. His research has explored the role of immune checkpoints such as B7-H3 and Tim-3 in colorectal and gastric cancers, as well as the impact of microRNAs on immune regulation in inflammatory diseases. His skills include molecular biology techniques, immunological assays, cancer cell signaling analysis, and translational research aimed at developing novel therapeutic strategies.

🔬 Research Focus

  • His research has led to groundbreaking findings on the interactions between immune cells and cancer cells, with a particular emphasis on T cell-mediated immune responses. He has published extensively in prestigious journals such as Cancer Immunology, Immunotherapy, Cell Death & Disease, Mucosal Immunology, and Gut, further advancing the understanding of cancer immunology and potential therapeutic interventions.

🌎Conclusion

  • Dr. Tongguo Shi exemplifies scientific excellence and collaborative leadership in cancer research. His work has significantly advanced the understanding of tumor immunology, cancer metabolism, and immunotherapy through high-impact interdisciplinary collaborations. His strong publication record, mentorship, and institutional partnerships highlight his commitment to groundbreaking discoveries that benefit both scientific progress and patient outcomes.

📖Publications

  • Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn’s Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway
    Authors: J. Wang, Jiayu; Y. He, Yuxin; X. Zhu, Xingchao; J. Zhu, Jinghan; Z. Deng, Zilin; H. Zhang, Huan; Y. Chen, Yanjun; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Advanced Science, 2025

  • FASN Promotes Lipid Metabolism and Progression in Colorectal Cancer via the SP1/PLA2G4B Axis
    Authors: X. Liu, Xin; J. Lu, Jiachun; X. Ni, Xiangyu; Y. He, Yuxin; J. Wang, Jiayu; Z. Deng, Zilin; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Cell Death Discovery, 2025

  • Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer
    Authors: L. Xu, Liang; Y. Shen, Yu; C. Zhang, Chuanqiang; T. Shi, Tongguo; X. Sheng, Xuejuan
    Journal: Journal of Cellular and Molecular Medicine, 2025

  • The m6A Revolution: Transforming Tumor Immunity and Enhancing Immunotherapy Outcomes
    Authors: T. Shi, Tongguo; H. Zhang, Huan; Y. Chen, Yueqiu
    Journal: Cell & Bioscience, 2025

  • Exosome-Derived Proteins in Gastric Cancer Progression, Drug Resistance, and Immune Response
    Authors: J. Wang, Jiayu; H. Zhang, Huan; J. Li, Juntao; X. Ni, Xiangyu; W. Yan, Wenying; Y. Chen, Yueqiu; T. Shi, Tongguo
    Journal: Cellular & Molecular Biology Letters, 2024

Dengke Bao | Tumor biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Dengke Bao | Tumor biology | Best Researcher Award 

Dengke Bao, Ph.D., is a professor, Ph.D. supervisor, and Deputy Dean at the School of Pharmacy, Henan University. He is a recipient of the Excellent Youth Fund Project of the Henan Natural Science Foundation and the 2022 China Postdoctoral Science Foundation Funding. His research focuses on mitochondria-related mechanisms in tumorigenesis, cancer progression, and immune regulation. He has published 20+ SCI-indexed papers in top journals like Oncogene and Cell Death & Disease and serves as an editorial member for Scientific Reports. His work provides new insights into tumor microenvironment remodeling and drug resistance in cancer therapy.

Prof. Dr. Dengke Bao | Henan University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Dengke Bao holds a Ph.D. and has established himself as a distinguished professor and Ph.D. supervisor. His academic journey has been marked by excellence, leading to his recognition as a Program for Central Plains Youth Top Talent and a recipient of multiple prestigious research grants.

👨‍🏫Experience

  • Currently serving as the Deputy Dean of the School of Pharmacy at Henan University, Dengke Bao has played a pivotal role in advancing molecular diagnostics and therapy. He is also the Deputy Director of the Henan Engineering Research Center for Molecular Diagnosis and Therapy of Esophageal Cancer and the Director of the Laboratory of Biomarkers and Liquid Biopsy in Kaifeng. His work has significantly contributed to understanding mitochondria-related mechanisms in tumorigenesis, cancer progression, and tumor immune regulation.

🏆Awards and Recognitions

  • Dengke Bao has been honored with numerous awards, including the Excellent Youth Fund Project of the Henan Natural Science Foundation and recognition as a Young Core Instructor of Henan. He was also a recipient of the 2022 China Postdoctoral Science Foundation Funding, highlighting his exceptional contributions to the field of oncology research.

💡Skills and Certifications

  • With a deep expertise in tumor biology and the tumor microenvironment, Dengke Bao specializes in investigating mitochondrial damage-associated molecular patterns (DAMPs) and their role in inflammatory responses and cancer therapy resistance. His research combines molecular biology, oncology, and immunology to uncover new therapeutic strategies for hepatocellular carcinoma (HCC) and other malignancies.

🔬 Research Focus

  • Dengke Bao’s research is centered on understanding how mitochondrial damage-associated molecular patterns influence the tumor microenvironment and immune regulation. His groundbreaking study demonstrated that sorafenib treatment in HCC induces the release of mitochondrial DNA into the tumor microenvironment, promoting M2 macrophage polarization through TLR9 activation and enhancing sorafenib resistance. His findings offer a new perspective on targeting mitochondrial DAMPs to reprogram tumor-associated macrophages, providing novel strategies to improve therapeutic efficacy and overcome drug resistance in cancer treatment.

 📚 Publications and Editorial Roles

  • Dengke Bao has authored over 20 SCI-indexed papers as a first or corresponding author in high-impact journals, including Oncogene, Journal of Experimental & Clinical Cancer Research, and Cell Death & Disease. He also serves as an editorial member for Scientific Reports, further solidifying his influence in the field of cancer research.

🌎Conclusion

  • Given his exceptional research contributions, leadership, and impact in oncology, Dengke Bao is a highly suitable nominee for the Research for Best Researcher Award. His work is not only innovative but also holds great promise for improving cancer treatment and patient outcomes, making him a deserving recipient of this prestigious recognition.

📖Publications

  • TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway

    • Authors: J. Lei, Q. Zhu, J. Guo, D. Bao, R. Guo
    • Journal: Journal of Translational Medicine, 2024

  • Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

    • Authors: X. Yang, J. Zhang, Y. Cheng, H. Liu, D. Bao
    • Journal: European Journal of Clinical Microbiology and Infectious Diseases, 2023

  • PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress

    • Authors: H. Li, X. Yang, Y. Song, B. Wan, D. Bao
    • Journal: Veterinary Microbiology, 2023

Shan Su | Oncology | Best Researcher Award

Posted on by sciencefather

Dr. Shan Su | Oncology | Best Researcher Award

Professional Memberships:

  • Her membership with the International Association for the Study of Lung Cancer (IASLC) indicates her active participation in the global oncology research community, further enhancing her profile as a top researcher.
Dr. Shan Su ,Guangzhou Chest Hospital, China

Profile

Scopus

OrcID

🌱EARLY ACADEMIC PURSUITS

  • Shan Su began her academic journey with a strong focus on clinical oncology, immersing herself in the study of treatment methodologies and therapies for various types of cancer, especially lung cancer. Early in her career, her dedication to patient-centered treatment approaches led her to explore a range of therapeutic practices, including chemotherapy, targeted therapies, and immunotherapy.

💼 PROFESSIONAL ENDEAVORS

  • As the Chief Physician at Guangzhou Chest Hospital, Shan Su has taken on a prominent role in the field of oncology, specializing in advanced and innovative cancer treatments. Over her ten-year tenure, she has applied targeted therapy, immunotherapy, and even local microwave ablation to treat malignant tumors, focusing particularly on lung tumors. Her role involves not only treating patients but also leading clinical advancements and educating the next generation of oncology professionals.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

  • Dr. Su’s research has paved the way in studying complex interactions between malignancies and other diseases, notably tuberculosis (TB). Recognizing a gap in the understanding of cancer patients with concurrent TB, she led a pioneering cohort study—the largest of its kind worldwide—documenting unique treatment challenges and outcomes. Currently, she is spearheading the first international clinical study investigating the effects of combining first-line chemotherapy with immunotherapy for lung cancer patients who have active pulmonary TB, with a primary focus on evaluating the safety and efficacy of these combined treatments.

📚ACADEMIC CITES 

  • Throughout her career, Dr. Su’s research has been recognized and cited by numerous peers in the medical community, underscoring her contributions to oncology and her influence on cancer research. Her work in combining immunotherapy with chemotherapy for complex cases is particularly well-regarded, with citations reflecting the growing interest and importance of her findings.

🌍IMPACT AND INFLUENCE

  • Dr. Su’s work has influenced clinical practices on a global scale. Her expertise has contributed significantly to the understanding of complex cases involving co-occurring cancer and TB, impacting treatment protocols and inspiring other researchers to explore similar areas. As a member of the International Association for the Study of Lung Cancer (IASLC), she collaborates with a network of global oncology professionals to advance knowledge and share insights into lung cancer treatment.

🌟LEGACY AND FUTURE AND CONTRIBUTIONS

  • Looking forward, Dr. Su remains committed to advancing oncological treatments, especially for complex cases like cancer with tuberculosis. Her ongoing research projects hold great promise for improving patient outcomes and expanding treatment options, making her a pioneer in her field. Dr. Su’s legacy will likely include groundbreaking contributions to cancer therapy innovations, laying the foundation for future treatments and offering hope for patients worldwide.

📄Publications

  • The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
    Authors: Li, L., Zhang, H., Xie, Y., Cen, W., Koundal, D.
    Journal: Computational and Mathematical Methods in Medicine, 2022, 2022, 1475871
  • Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
    Authors: Su, S., Ye, M.-F., Cai, X.-T., Huang, H.-Y., Dong, Z.-Y.
    Journal: BMC Medicine, 2021, 19(1), 322
  • Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival
    Authors: Chen, R.-L., Zhou, J.-X., Cao, Y., Wang, S.-Y., Lin, L.-Z.
    Journal: Frontiers in Immunology, 2020, 11, 1933
  • Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing
    Authors: Su, S., Zou, J.-J., Zeng, Y.-Y., Zhao, Z.-G., Liu, J.-X.
    Journal: BioMed Research International, 2019, 2019, 6096350
  • Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy
    Authors: Zou, J., Su, S., Chen, Z., Xia, Y., Huang, D.
    Journal: Artificial Cells, Nanomedicine and Biotechnology, 2019, 47(1), pp. 3456–3464